Published in ACS Nano on February 23, 2015
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. Mol Pharm (2015) 0.87
Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.83
Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol Pharm (2016) 0.81
Pigment epithelial-derived factor gene loaded novel COOH-PEG-PLGA-COOH nanoparticles promoted tumor suppression by systemic administration. Int J Nanomedicine (2016) 0.78
Current Approaches of Photothermal Therapy in Treating Cancer Metastasis with Nanotherapeutics. Theranostics (2016) 0.77
Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine (Lond) (2016) 0.77
miRNA nanotherapeutics for cancer. Drug Discov Today (2016) 0.75
Highlights from the latest articles in nanomedicine for reproductive oncology. Nanomedicine (Lond) (2015) 0.75
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces (2016) 0.75
Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. PLoS One (2016) 0.75
Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release (2016) 0.75
In Vitro Neurotoxicity Resulting from Exposure of Cultured Neural Cells to Several Types of Nanoparticles. J Cell Death (2017) 0.75
Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts. Theranostics (2017) 0.75
Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Oncotarget (2015) 0.75
Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics (2017) 0.75
Ultrasound-guided drug delivery in cancer. Ultrasonography (2017) 0.75
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res (2005) 9.80
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood (2007) 5.14
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res (2008) 3.70
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release (2007) 3.20
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater (2011) 2.84
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets (2009) 1.87
Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther (2010) 1.81
Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res (2011) 1.64
Role of miR-10b in breast cancer metastasis. Breast Cancer Res (2010) 1.39
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 1.30
Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol (2011) 1.22
Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. Bioessays (2010) 1.21
miRNA: the new gene silencer. Am J Clin Pathol (2007) 1.19
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol Ther Nucleic Acids (2013) 1.14
Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed (2010) 1.10
MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci (2010) 1.08
Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res (2011) 1.02
Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol (2009) 1.02
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol (2009) 1.01
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm (2012) 0.96
Beyond HPV: oncomirs as new players in cervical cancer. FEBS Lett (2008) 0.95
Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc Chem Res (2011) 0.93
Delivery of MicroRNA-10b with Polylysine Nanoparticles for Inhibition of Breast Cancer Cell Wound Healing. Breast Cancer (Auckl) (2011) 0.91
High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Res Treat (2011) 0.90
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Influence of hydrophilic surfactants on the properties of multiple W/O/W emulsions. J Colloid Interface Sci (2009) 0.90
Therapeutic evaluation of microRNAs by molecular imaging. Theranostics (2013) 0.88
Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale (2013) 0.82
Antagonizing metastasis. Nat Biotechnol (2010) 0.77